University of Connecticut School of Pharmacy, Department of Pharmaceutical Sciences, Storrs, CT 06269-3092, USA.
Hepatology. 2011 Sep 2;54(3):969-78. doi: 10.1002/hep.24464. Epub 2011 Jul 27.
Acetaminophen (APAP) is safe at therapeutic dosage but can cause severe hepatotoxicity if used at overdose. The mechanisms of injury are not yet fully understood, but previous reports had suggested that the mitochondrial permeability transition (mPT) may be involved in triggering hepatocellular necrosis. We aimed at inhibiting mitochondrial cyclophilin D (CypD), a key regulator of the mPT, as a potential therapeutic target in APAP hepatotoxicity. Wildtype mice treated with a high dose of APAP (600 mg/kg, intraperitoneal) developed typical centrilobular necrosis, which could not, however, be prevented by cotreatment with the selective CypD inhibitor, Debio 025 (alisporivir, DEB025, a nonimmunosuppressive cyclosporin A analog). Similarly, genetic ablation of mitochondrial CypD in Ppif-null mice did not afford protection from APAP hepatotoxicity. To determine whether APAP-induced peroxynitrite stress might directly activate mitochondrial permeabilization, independently of the CypD-regulated mPT, we coadministered the peroxynitrite decomposition catalyst Fe-TMPyP (10 mg/kg, intraperitoneal, 90 minutes prior to APAP) to CypD-deficient mice. Liver injury was greatly attenuated by Fe-TMPyP pretreatment, and mitochondrial 3-nitrotyrosine adduct levels (peroxynitrite marker) were decreased. Acetaminophen treatment increased both the cytosolic and mitochondria-associated P-JNK levels, but the c-jun-N-terminal kinase (JNK) signaling inhibitor SP600125 was hepatoprotective in wildtype mice only, indicating that the JNK pathway may not be critically involved in the absence of CypD.
These data support the concept that an overdose of APAP results in liver injury that is refractory to pharmacological inhibition or genetic depletion of CypD and that peroxynitrite-mediated cell injury predominates in the absence of CypD.
醋氨酚(APAP)在治疗剂量下是安全的,但如果过量使用,会导致严重的肝毒性。其损伤机制尚未完全阐明,但先前的报告表明,线粒体通透性转换(mPT)可能参与触发肝细胞坏死。我们旨在抑制线粒体亲环素 D(CypD),作为 APAP 肝毒性的潜在治疗靶点,CypD 是 mPT 的关键调节因子。用大剂量 APAP(600mg/kg,腹腔内)处理的野生型小鼠会产生典型的中央小叶坏死,但用选择性 CypD 抑制剂 Debio 025(alisporivir,DEB025,一种非免疫抑制环孢素 A 类似物)联合治疗并不能预防这种情况。同样,在 Ppif 基因敲除小鼠中敲除线粒体 CypD 也不能防止 APAP 肝毒性。为了确定 APAP 诱导的过氧亚硝酸盐应激是否可能直接激活线粒体通透性,而不依赖 CypD 调节的 mPT,我们向 CypD 缺陷型小鼠同时给予过氧亚硝酸盐分解催化剂 Fe-TMPyP(10mg/kg,腹腔内,APAP 前 90 分钟)。Fe-TMPyP 预处理大大减轻了肝损伤,同时降低了线粒体 3-硝基酪氨酸加合物水平(过氧亚硝酸盐标志物)。醋氨酚处理增加了细胞质和线粒体相关的 P-JNK 水平,但 c-jun-N-末端激酶(JNK)信号抑制剂 SP600125 仅在野生型小鼠中具有肝保护作用,表明在 CypD 缺乏的情况下,JNK 途径可能不是关键的。
这些数据支持这样一种观点,即过量的 APAP 会导致肝损伤,这种损伤对 CypD 的药理学抑制或基因耗竭具有抗性,并且在 CypD 缺乏的情况下,过氧亚硝酸盐介导的细胞损伤占主导地位。